256 related articles for article (PubMed ID: 19640206)
1. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
[TBL] [Abstract][Full Text] [Related]
2. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
3. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Forouzannia A; Richards GM; Khuntia D; Mehta MP
Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
[TBL] [Abstract][Full Text] [Related]
4. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.
Evens AM
Curr Opin Oncol; 2004 Nov; 16(6):576-80. PubMed ID: 15627019
[TBL] [Abstract][Full Text] [Related]
5. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
6. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
7. Advances in radiation therapy of brain metastasis.
Lo SS; Sahgal A; Ma L; Chang EL
Prog Neurol Surg; 2012; 25():96-109. PubMed ID: 22236671
[TBL] [Abstract][Full Text] [Related]
8. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
9. Whole-brain radiotherapy in the management of brain metastasis.
Khuntia D; Brown P; Li J; Mehta MP
J Clin Oncol; 2006 Mar; 24(8):1295-304. PubMed ID: 16525185
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
Carde P; Timmerman R; Mehta MP; Koprowski CD; Ford J; Tishler RB; Miles D; Miller RA; Renschler MF
J Clin Oncol; 2001 Apr; 19(7):2074-83. PubMed ID: 11283141
[TBL] [Abstract][Full Text] [Related]
11. A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
Drzymala RE; Wasserman TH; Won M; Shaw E; Cmelak AJ; Loeffler J; Souhami L;
Radiother Oncol; 2008 Apr; 87(1):89-92. PubMed ID: 18342381
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemotherapy and radiotherapy in patients with brain tumors.
Glantz MJ; Kim L; Choy H; Akerley W
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):78-82. PubMed ID: 10550830
[TBL] [Abstract][Full Text] [Related]
13. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
14. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.
Mehta MP; Shapiro WR; Glantz MJ; Patchell RA; Weitzner MA; Meyers CA; Schultz CJ; Roa WH; Leibenhaut M; Ford J; Curran W; Phan S; Smith JA; Miller RA; Renschler MF
J Clin Oncol; 2002 Aug; 20(16):3445-53. PubMed ID: 12177105
[TBL] [Abstract][Full Text] [Related]
15. Past, current and future protocols for combined modality therapy in childhood medulloblastoma.
Kaaijk P; Schouten-van Meeteren AY; Slotman BJ; Kaspers GJ
Expert Rev Anticancer Ther; 2003 Feb; 3(1):79-90. PubMed ID: 12597352
[TBL] [Abstract][Full Text] [Related]
16. Motexafin gadolinium: a novel redox active drug for cancer therapy.
Magda D; Miller RA
Semin Cancer Biol; 2006 Dec; 16(6):466-76. PubMed ID: 17112739
[TBL] [Abstract][Full Text] [Related]
17. [Recent management of metastatic brain tumors].
Abe M; Tabuchi K
No To Shinkei; 2005 Dec; 57(12):1058-66. PubMed ID: 16375191
[No Abstract] [Full Text] [Related]
18. Clinical trials referral resource. Clinical trials with gadolinium-texaphyrin and lutetium-texaphyrin.
Ivy SP; Blatner G; Cheson BD
Oncology (Williston Park); 1999 May; 13(5):671, 674-6. PubMed ID: 10356686
[No Abstract] [Full Text] [Related]
19. Novel radiosensitizers for tumors of the central nervous system.
Mehta MP; Suh JH
Curr Opin Investig Drugs; 2004 Dec; 5(12):1284-91. PubMed ID: 15648950
[TBL] [Abstract][Full Text] [Related]
20. Motexafin gadolinium in the treatment of brain metastases.
Richards GM; Mehta MP
Expert Opin Pharmacother; 2007 Feb; 8(3):351-9. PubMed ID: 17266469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
